vaccine, developed by private Chinese pharmaceutical firm Sinovac Biotech, became the third in the world to enter Phase 3 clinical trials, or large-scale testing on humans - the last step before regulatory approval, news agency AFP reported.Around 9,000 health workers across six Brazilian states will receive the vaccine, known as CoronaVac, in two doses over the next three months under the study.
The initial results are expected in three months.Brazil is the second-hardest-hit country in the coronavirus pandemic, after the United States.Another experimental coronavirus vaccine, developed by Oxford University and pharmaceutical firm AstraZeneca, is also undergoing final stage trial in Brazil.